Deutsch

Case Studies · Healthcare / MedTech · 0-10M ARR

The Product Worked. The Business Model Didn't.

A venture-backed healthcare company with a hardware-software product was struggling with revenue growth despite strong product-market signals. Uhlig Capital joined the board and took on an interim CPO role. The analysis showed a structurally unprofitable business model. A disciplined process followed to redesign the model, validate it with the strategic investor and secure the next funding round.

35%EBITDA Margin

What happened

The client stays unnamed because these mandates are confidential.

The Situation

The company had built a compelling healthcare product that combined proprietary hardware with a software layer. The technology worked and customers were using it, but revenue growth had stalled and the team could not explain why.

The founder and the existing investors were frustrated. The product was good and the market was real, yet the numbers were not moving in the right direction. Hiring more salespeople had not changed that, and neither had adjusting the pricing. The assumption was that the problem sat somewhere in execution. It did not.

The business model itself was structurally unprofitable. Unit economics did not work at scale, because delivering the combined hardware-software product cost more than the market was willing to pay under the existing model. No amount of sales optimization could fix that.

None of this was obvious from the outside. It became visible only through a structured analysis of the entire value chain, from production and delivery through to customer lifetime value and margin contribution.

Approach

Uhlig Capital joined the board and at the same time took on an interim CPO role, working inside the company to understand the product, the market and the economics from the ground up.

Diagnostic: Understanding the Real Problem

The first step was a thorough analysis of the existing business model. Revenue streams, cost structures, unit economics, customer acquisition costs and margin profiles were mapped end to end. The current model could not deliver profitable growth, however well the company executed. The problem was structural, and neither sales nor pricing would solve it.

Business Model Redesign

With the diagnosis in hand, the team started a structured process to identify and evaluate alternative business models. Several options were developed, each with a detailed financial projection and a clear set of assumptions. The work was done in close collaboration with the strategic investor, so that everyone stayed aligned at every step.

Each model was stress-tested against realistic market assumptions, customer willingness to pay and operational feasibility. The team was looking for the model that could actually deliver sustainable EBITDA margin improvement, which was not always the most exciting one on paper.

Validation with the Strategic Investor

The strategic investor was involved throughout the evaluation. Models were presented, discussed, challenged and refined in a series of working sessions. Nobody was pitching. Both sides were looking for the right way forward, on the basis of data and shared conviction.

One model emerged as the strongest candidate. It restructured the revenue logic, shifted the margin profile and created a path to profitability the old model could never have delivered.

Financial Planning and Funding Round

With the new business model validated, Uhlig Capital built the financial plan for the transition. It quantified the investment required, the timeline to profitability and the milestones to hit along the way.

On this foundation, the company approached the next funding round, and Uhlig Capital supported the process from preparation through closing. A clearly diagnosed problem, a validated solution and a credible financial plan gave investors the confidence to commit.

Outcome

The company secured a new funding round, backed by a business model that had been rigorously tested and validated with the strategic investor.

The new model fundamentally changed the company’s economics. A structurally unprofitable product became a viable, scalable business, and revenue growth resumed on a healthier foundation.

The board gained a shared understanding of what really drove the company’s performance. Decisions no longer rested on assumptions about execution gaps. They rested on a clear picture of where value was created and where it was destroyed.

The interim CPO role ended once the new model was in place and the internal team was equipped to execute it. Uhlig Capital’s board involvement continued through the transition period.

Key Takeaways

When growth stalls, question the model before questioning the team. Execution problems are common, but sometimes the business model itself is the constraint. No amount of optimization can fix a model that is structurally broken.

Hardware-software businesses carry hidden margin traps. Delivering physical and digital products together creates complex cost structures that can easily mask unprofitability. End-to-end unit economics have to be visible and honest.

Investor alignment comes from the process. Involving the strategic investor in the evaluation of alternatives gave it shared ownership of the outcome. The funding round succeeded because the investor had taken part in the work and had not merely been shown the conclusion.

A CPO also answers for the business model. Why customers buy, how value is delivered and where margin is created or lost are all product leadership questions. In this case, answering them is what got growth moving again.

In their words

CEO

“Everyone kept telling us to sell harder. It took someone sitting inside the company to see that the problem was not how we sold, but what we sold and how we charged for it. That insight changed the entire trajectory.”

Some effects on this site were built by others. This is their work.

— Credits